|Mr. Nikolaj SÃ¸rensen||Pres & CEO||5.29M||N/A||1972|
|Mr. Joseph DeFeo||EVP & CFO||N/A||N/A||1961|
|Ms. Cecilia Coupland||VP & Head of Operations||N/A||N/A||1976|
|Lena Wange||Head of Investor Relations & Communications Director||N/A||N/A||N/A|
|Dr. Michael Sumner M.D.||Chief Medical Officer||N/A||N/A||1965|
|Mr. Johannes Doll||Exec. VP & Chief Commercial Officer||N/A||N/A||1981|
|Mr. Robert RÃ¶nn||VP and Head of R&D||N/A||N/A||1976|
|Mr. Dennis Urbaniak||Exec. VP of Digital Health||N/A||N/A||1969|
|Mr. Robert A. Deluca||Pres of Orexo US Inc||N/A||N/A||1961|
|Mr. Jesper Lind||Advisor||N/A||N/A||1960|
Orexo AB (publ), a specialty pharmaceutical company, and its subsidiaries develop and commercialize pharmaceuticals and digital therapies in the United States. Its products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar, for the treatment of short-term insomnia. The company's development products comprise OX124, a medication for naloxone rescue; OX125, a medication for nalmefene rescue; OX338 sublingual tablet formulation of ketorolac for acute treatment of moderate to severe pain; and OX382, an oral formulation of buprenorphine and naloxone for treatment of opioid dependence. It is also developing OX-MPI program that has lead candidate drug BI1029539, an anti-inflammatory compound targeting microsomal prostaglandin E synthase. The company's digital therapies comprise OXD01 for opioid use disorder and OXD02/vorvida for alcohol use disorder. Orexo AB (publ) has partnerships with Lyfebulb to recover from alcohol and opioid use disorders; and GoGoMeds to provide digital therapies deprexis and vorvida available for the treatment of depression and management of problematic alcohol misuse. The company was founded in 1995 and is headquartered in Uppsala, Sweden.
Orexo AB (publ)’s ISS Governance QualityScore as of December 2, 2020 is 7. The pillar scores are Audit: 1; Board: 3; Shareholder Rights: 1; Compensation: 10.